Q4 2024 Medivir AB Earnings Call Transcript

Feb 18, 2025 / 01:00 PM GMT

Release Date Price: kr2.09 (-10.30%)

Transcript

Key Points

Positve

Medivir AB (FRA:MVR0) successfully closed its Phase 1B/2A study for its liver cancer treatment, with patients transitioning to compassionate use.
The company received FDA IND approval for its Phase 2B study, named Focus 2, marking a significant milestone.
A clinical collaboration and supply agreement with ASI has been established, enhancing development efforts.
The company is progressing with plans to expand its study to 8 countries and 40 sites, aiming for a global reach.
Medivir AB (FRA:MVR0) has shown promising clinical benefits in its fostrox plus Lenvima combination, with data indicating a longer time to progression compared to Lenvima monotherapy.

Negative

The operating loss for Q4 was higher than the previous year, primarily due to increased clinical costs.
There is a lack of approved treatments for second-line liver cancer, posing a challenge in establishing market presence.
The company faces significant competition in the first-line treatment market, with many PD-1 combinations in development.
External expenses increased due to clinical study preparations, impacting financial performance.
The cash balance, while sufficient for current plans, relies on support from the main shareholder, indicating potential financial constraints.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MEDIVIR.ST - Medivir AB
Q4 2024 Medivir AB Earnings Call
Feb 18, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you and good afternoon and welcome everyone to the Medi Quarter 4 report where we will sort of go through sort of the progress made in the last quarter of 2024 and then looking ahead to what is about to happen in 2025.

Yeah.

We quarter 4 last year continued to be a good quarter with regards to momentum in our primary program, for strokes, which is our sort of oral liver targeted treatment in development for advanced, liver cancer.

We were, we closed our phase 1 B Phase 2A study of hostructure in combination with Lenvima, and we are very much looking forward to presenting the final data at the EAS liver cancer summit, and that is actually taking place this week on Thursday.

We closed the study while still

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.